


Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature

SUPPLEMENTARY FIGURE



Supplementary Figure S1: RAS pathway activity and cetuximab sensitivity in clinical trial CA225-045. Waterfall plot of RAS signature scores in the patients who experienced disease control (25; blue) or progressive disease (43; red) after cetuximab therapy. Results for three patients of Asian origin are indicated. The Y axis shows RAS signature score relative to the mean in this dataset. Scores were derived using microarray data from GSE5851 in the GEO database.